Search Results - "Geyvandova, N. I."

Bicyclol in the treatment of patients with chronic diffuse liver diseases by Maevskaya, M. V., Lunkov, V. D., Geyvandova, N. I., Palgova, L. K., Pirogova, I. Yu, Prashnova, M. K., Marchenko, N. V., Zinovieva, E. N., Ilchishina, T. A., Ivashkin, V. T., Koroy, P. V.

“…Introduction . The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with morbidity and mortality from liver…”
Get full text

Experience of therapy of chronic viral hepatitis c patients with unfavourable response predictors by N. I. Geyvandova, A. V. Lipov, P. V. Koroy, A. V. Yagoda, S. S. Rogova

“…Introduction in practice of therapeutic establishments in the RF of antiviral therapy of chronic viral hepatitis in the form of interferon-free schemes led to…”
Get full text

Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement) by M. V. Maevskaya, M. Yu. Nadinskaia, E. N. Bessonova, N. I. Geyvandova, M. S. Zharkova, E. A. Kitsenko, N. V. Korochanskaya, I. A. Kurkina, A. L. Melikyan, V. G. Morozov, Yu. V. Khoronko, T. A. Deeva, K. A. Gulyaeva, V. T. Ivashkin

“…Introduction. As a result of portal hypertension (sequestration of platelets in an enlarged spleen) and liver failure (decreased production of thrombopoietin…”
Get full text

The role of thrombocytopenia in the clinical management of patients with liver cirrhosis: opinion of experts in therapeutic and surgical hepatology by Maevskaya, M. V., Bessonova, E. N., Geyvandova, N. I., Kitsenko, E. A., Korochanskaia, N. V., Morozov, V. G., Khoronko, Y. V.

“…Seven of the country’s leading  experts  in the field of therapeutic and surgical hepatology answer  questions on this issue: how relevant  is thrombocytopenia…”
Get full text

Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines by Maevskaya, M. V., Zharkova, M. S., Ivashkin, V. T., Bessonova, E. N., Geyvandova, N. I., Kitsenko, E. A., Korochanskaya, N. V., Kurkina, I. A., Melikyan, A. L., Morozov, V. G., Khoronko, Yu. V.

“…Hemostasis disorders in cirrhosis / severe liver disease are complex, as they affect both pro- and anticoagulant factors, as well as pro- and antifibrinolytic…”
Get full text

Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks by Manns, M. P., Wedemeyer, H., Singer, A., Khomutjanskaja, N., Dienes, H. P., Roskams, T., Goldin, R., Hehnke, U., Inoue, H.

“…Chronic hepatitis C patients often fail to respond to interferon‐based therapies. This phase III study aimed at confirming the efficacy and safety of…”
Get full text

The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities by Maevskaya, Marina V., Kotovskaya, Yulia V., Ivashkin, Vladimir T., Tkacheva, Olga N., Troshina, Ekaterina A., Shestakova, Marina V., Breder, Valeriy V., Geyvandova, Natalia I., Doshchitsin, Vladimir L., Dudinskaya, Ekaterina N., Ershova, Ekaterina V., Kodzoeva, Khava B., Komshilova, Ksenia A., Korochanskaya, Natalia V., Mayorov, Alexander Yu, Mishina, Ekaterina E., Nadinskaya, Maria Yu, Nikitin, Igor G., Pogosova, Nana V., Tarzimanova, Aida I., Shamkhalova, Minara Sh

“…The National Consensus was prepared with the participation of the National Medical Association for the Study of the Multimorbidity, Russian Scientific Liver…”
Get full text

The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience) by M. Sh. Khubutiya, V. E. Syutkin, N. I. Geyvandova, A. A. Salienko, T. V. Gudzovskaya, M. S. Novruzbekov

“…Authors reviewed published data concerning antiviral treatment of liver transplant recipients with 1st generation HCV protease inhibitors (telaprevir and…”
Get full text

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program by V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina

“…Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities…”
Get full text

Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12) by V. T. Ivashkin, I. G. Bakulin, P. O. Bogomolov, M. V. Matsiyevich, N. I. Geyvandova, P. V. Koroy, S. V. Nedogoda, O. A. Sablin, L. G. Lenskaya, Ye. V. Beloborodova, A. A. Bagretsova, R. A. Abdulkhakov, M. F. Osipenko, I. V. Osipova, D. A. Pocheptsov, Ye. V. Chumachek, O. M. Khromtsova, Ye. V. Kuzmicheva

“…Aim of investigation. To estimate efficacy and safety of two pharmacological forms of «Phosphogliv» (lyophilizate for intravenous administration and capsules)…”
Get full text

Efficacy and safety of glycyrrhizic acid and essential phospholipids (Phosphogliv) combination for alcoholic liver disease: results of the double-blind randomized placebo-controlled multicenter post-registration (phase IV) clinical trial «Jaguar» (PHG-M2/P03-12) by I. G. Bakulin, N. A. Bokhan, P. O. Bogomolov, N. I. Geyvandova, M. V. Matsiyevich, M. A. Vinnikova, V. G. Morozov, O. M. Khromtsova, G. S. Soldatova, O. Yu. Shiryayev, R. D. Ilyuk, K. V. Rybakova, A. G. Katkovskaya, S. V. Teplykh, A. A. Bagretsova, M. V. Krasnova, Ye. V. Alekseyeva, A. V. Anipchenko, Ye. V. Baskakov

“…Material and methods. The original study included overall 120 patients with ALD, who were randomized in two identical groups. The patients of the main group…”
Get full text

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Mayevskaya, M.V., Ivashkin, V.T., Bessonova, Ye.N., Bogomolov, P.O., Geyvandova, N.I., Zhdanov, K.V., Morozov, V.G., Pasechnikov, V.D., Khomenko, I.Yu, Yagoda, A.V.

“…Aim of investigation. Nowadays the question, whether pegylated interferon should be completely abandoned in the treatment of chronic hepatitis C (CHC) is still…”
Get full text

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study) by M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov

“…Aim of investigation. To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at…”
Get full text

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study by V. T. Ivashkin, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, M. V. Mayevskaya, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda

“…Aim of investigation. Comparative assessment of efficacy and safety of Pegaltevir and PegIntron in within pattern of combined antiviral therapy in previously…”
Get full text

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

“…Aim of investigation. HEP3002 is the international early access program of efficacy and safety estimation of telaprevir in combination to peginterferon alpha…”
Get full text